Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 04, 2019 10:02 ET | Source: Myriad Genetics, Inc.

GeneSight® GUIDED Study Published in the Journal of Psychiatric Research

SALT LAKE CITY, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced the publication of the landmark GeneSight GUIDED...
December 31, 2018 07:05 ET | Source: Myriad Genetics, Inc.

Peter D. Meldrum (1947-2018)

SALT LAKE CITY, Dec. 31, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) today announced that the company’s former CEO Peter Durkee Meldrum, age 71, passed away on Thursday, December...
December 27, 2018 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Present at the 37th Annual J.P. Morgan Healthcare Conference

SALT LAKE CITY, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 37th...
December 26, 2018 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Announces Publication of Vectra® Study in Journal Rheumatology

SALT LAKE CITY, Dec. 26, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced the results from a large commercial cohort and...
December 19, 2018 13:10 ET | Source: Myriad Genetics, Inc.

BRACAnalysis CDx® Approved by U.S. Food and Drug Administration as Companion Diagnostic for AstraZeneca’s Lynparza® (olaparib) in Patients with Advanced-Stage, BRCA-Mutated Ovarian Cancer

SALT LAKE CITY, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug...
December 19, 2018 07:05 ET | Source: Myriad Genetics, Inc.

EndoPredict® Test Receives Positive NICE Recommendation for Patients with Early Breast Cancer

SALT LAKE CITY, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that the United Kingdom’s (UK) National Institute...
December 07, 2018 08:32 ET | Source: Myriad Genetics, Inc.

Prospective Study Demonstrates EndoPredict® Can Guide Chemotherapy Decision For Women with Early-Stage Breast Cancer

SALT LAKE CITY, Dec. 07, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that academic researchers from the Technical...
December 07, 2018 08:30 ET | Source: Myriad Genetics, Inc.

Myriad Announces Important New Data for Its EndoPredict® Breast Cancer Test Will Be Presented at the 2018 San Antonio Breast Cancer Symposium

SALT LAKE CITY, Dec. 07, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that new data on its EndoPredict® test will be...
December 06, 2018 08:30 ET | Source: Myriad Genetics, Inc.

Myriad Validates Polygenic Score to Predict Breast Cancer Risk in Women of Hispanic Ancestry Who Test Negative for Hereditary Cancer Mutations

SALT LAKE CITY, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced results from an important study...
November 19, 2018 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Announces $50 Million Accelerated Share Repurchase Program

SALT LAKE CITY, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that the company has entered into an accelerated...